All PlansCoverageMedium impact
24-073 Amjevita Now Available for Treatment of Inflammatory Diseases
Health Net·CA · Rheumatology, Gastroenterology, Dermatology +2 more·Pharmacy
Effective date
Dec 12, 2023
We identified it
Jun 20, 2026
Summary
Amjevita (adalimumab-atto), a biosimilar to Humira, has been added to the CCHCS Drug Formulary for treating inflammatory conditions including rheumatoid arthritis and other autoimmune diseases. CDCR primary care providers must sign therapeutic interchange agreements allowing automatic switching from Humira to Amjevita.
Action Required
CDCR primary care providers must sign therapeutic interchange agreements to allow pharmacy to switch all patients from Humira to Amjevita. Update prescribing protocols to use Amjevita as the preferred adalimumab product for inflammatory conditions. Follow CCHCS non-formulary approval process if prescribing non-formulary alternatives.